Informações:
Falhas:
ID
38832
Descrição
Variation of Glucose Values at Early Stages of Diabetes - Continuous Glucose Monitoring; ODM derived from: https://clinicaltrials.gov/show/NCT02294370
Link
https://clinicaltrials.gov/show/NCT02294370
Palavras-chave
Versões (1)
- 07/11/2019 07/11/2019 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
7 de novembro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Diabetes Mellitus, Type 2 NCT02294370
Eligibility Diabetes Mellitus, Type 2 NCT02294370
- StudyEvent: Eligibility
Similar models
Eligibility Diabetes Mellitus, Type 2 NCT02294370
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Decreased glucose tolerance | Plasma Glucose Measurement Oral Glucose Tolerance Test | Diabetes Mellitus, Non-Insulin-Dependent | Plasma fasting glucose measurement | Pregnancy Absent
Item
individuals with impaired glucose tolerance (2h plasma glucose during oral glucose tolerance test >7.8-11.1 mmol/l, n=50) or with type 2 diabetes (fasting plasma glucose > 7.0 mmol/l and/or 2h plasma glucose > 11.1 mmol/l on two occasions, or both criteria fulfilled in the same oral glucose tolerance test while not pregnant, n=50) with short duration (<3 years); 40 from padova university hospital, 60 from the botnia study or the ppp (prevalence, prediction, prevention)-botnia study in finland.
boolean
C0151671 (UMLS CUI [1])
C0202042 (UMLS CUI [2,1])
C0029161 (UMLS CUI [2,2])
C0011860 (UMLS CUI [3])
C0583513 (UMLS CUI [4])
C0032961 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
C0202042 (UMLS CUI [2,1])
C0029161 (UMLS CUI [2,2])
C0011860 (UMLS CUI [3])
C0583513 (UMLS CUI [4])
C0032961 (UMLS CUI [5,1])
C0332197 (UMLS CUI [5,2])
Age
Item
age 40-75 years
boolean
C0001779 (UMLS CUI [1])
Insulin | GLP-1 Analogue | Sulfonylurea | Adrenal Cortex Hormones Oral | Thyreostatic therapy | Thyroid Hormones | LH-RH Analogs
Item
medication with: insulin, glucagon-like peptide-1 (glp-1)-analogues, sulphonylureas, oral corticosteroids, thyreostatic agents or thyroid hormone, luteinizing-hormone-releasing hormone (lhrh) analogues
boolean
C0021641 (UMLS CUI [1])
C3273809 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C0001617 (UMLS CUI [4,1])
C1527415 (UMLS CUI [4,2])
C1696471 (UMLS CUI [5])
C0040135 (UMLS CUI [6])
C1518041 (UMLS CUI [7])
C3273809 (UMLS CUI [2])
C0038766 (UMLS CUI [3])
C0001617 (UMLS CUI [4,1])
C1527415 (UMLS CUI [4,2])
C1696471 (UMLS CUI [5])
C0040135 (UMLS CUI [6])
C1518041 (UMLS CUI [7])
Pregnancy
Item
pregnancy
boolean
C0032961 (UMLS CUI [1])
Change Ophthalmoscopy Retinal
Item
known changes in retinal fundus photographs
boolean
C0392747 (UMLS CUI [1,1])
C0029090 (UMLS CUI [1,2])
C0035298 (UMLS CUI [1,3])
C0029090 (UMLS CUI [1,2])
C0035298 (UMLS CUI [1,3])
Microalbuminuria
Item
known, microalbuminuria
boolean
C0730345 (UMLS CUI [1])
Hemoglobin A1c measurement
Item
hba1c >8%
boolean
C0474680 (UMLS CUI [1])
Plasma fasting glucose measurement
Item
fasting plasma glucose >10 mmol/l
boolean
C0583513 (UMLS CUI [1])
Metformin allowed | Thiazolidinediones allowed | Gliptins To be stopped | Acarbose To be stopped
Item
medication with metformin, glitazones, gliptins (or acarbose) is allowed but gliptins and acarbose need to be stopped 2 days before testing and during the study
boolean
C0025598 (UMLS CUI [1,1])
C0683607 (UMLS CUI [1,2])
C1257987 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C1827106 (UMLS CUI [3,1])
C1272691 (UMLS CUI [3,2])
C0050393 (UMLS CUI [4,1])
C1272691 (UMLS CUI [4,2])
C0683607 (UMLS CUI [1,2])
C1257987 (UMLS CUI [2,1])
C0683607 (UMLS CUI [2,2])
C1827106 (UMLS CUI [3,1])
C1272691 (UMLS CUI [3,2])
C0050393 (UMLS CUI [4,1])
C1272691 (UMLS CUI [4,2])